CVS Caremark & Zepbound in 2026: Coverage Is Coming Back

If you’re on a CVS Caremark plan and you’ve been paying full price for Zepbound — or were forced onto Wegovy last year — the picture is about to change. On May 28, 2026, CVS Caremark announced it will bring Zepbound back to its standard formulary this fall, ending one of the most contested coverage decisions of the GLP-1 era. Here’s exactly what’s changing, when, what it costs, and what to do in the meantime if you can’t wait until October.

The quick answer

CVS Caremark will cover Zepbound again starting October 1, 2026, as a co-preferred option on the standard commercial formulary template used by roughly 25–30 million Americans. The oral pill Foundayo was added June 1, 2026. Once covered, eligible commercially insured members can expect to pay about $25 a month; Medicare Part D members can pay a flat $50 a month for Wegovy or Zepbound through the GLP-1 Bridge program beginning July 1, 2026. The one catch: employers can still opt out, so co-preferred status doesn’t guarantee your plan pays.

The timeline at a glance

What happened, and why it reversed

In July 2025, CVS Caremark became the only major pharmacy benefit manager to drop Zepbound while keeping Novo Nordisk’s Wegovy, after Novo struck a formulary-access deal. The company said standardizing on one GLP-1 controlled costs, but patients pushed back hard — many had lost more weight on tirzepatide and regained some after being switched to semaglutide — and a class-action lawsuit followed. Roughly a year later, after fresh negotiations with both manufacturers, CVS reversed course, saying the deals generated 10–15% additional savings across the class. The result: both Lilly’s and Novo’s products will sit side by side as co-preferred options.

The reversal also signals where the wider GLP-1 market is heading in 2026. Payers spent the year fighting the cost of a drug class millions of people want, and the fixes arriving now — manufacturer copay deals, the Medicare GLP-1 Bridge, and a new oral option in Foundayo — are all aimed at the same problem: coverage, not clinical evidence, is the biggest barrier to staying on these medications. For patients, the practical takeaway is that the cheapest path keeps shifting. A year ago, a CVS Caremark member’s best move was often to switch drugs or pay cash; after October 1, it may be a $25 copay; and for anyone whose plan won’t cover weight-loss GLP-1s at all, the compounded route remains the only sub-$200 way to the same molecule. The lesson is to re-check your options every few months, because the numbers that define “cheapest” are moving faster in this category than almost any other in medicine.

What it actually costs you

The headline numbers are genuinely good — if your plan covers GLP-1s for weight loss. Eligible commercially insured members can expect roughly $25/mo for Zepbound or Foundayo once coverage is active. Medicare Part D members get a flat $50/mo for Wegovy or Zepbound via the GLP-1 Bridge. But the gap between “on the formulary” and “covered by your plan” is where people get caught: self-funded employers can exclude weight-loss GLP-1s entirely. So before you celebrate, confirm with your HR or plan that GLP-1s for weight management are covered at all.

The coverage cliff — and the steady alternative

For a CVS Caremark member, the cost of staying on Zepbound has been a cliff: a manageable copay in early 2025, then full cash price through the exclusion, then back down to about $25 once October arrives. Plotted over time, that volatility is the whole story — and it’s why many people bridged the gap with compounded tirzepatide, which held a flat price the entire time.

Your options until October 1 (or if your plan opts out)

If you’re covered for Wegovy today and happy on it, you may simply wait for Zepbound to return. If not, here are the realistic paths:

• Switch to Wegovy — CVS Caremark’s currently preferred GLP-1 for weight loss. Different molecule (semaglutide), but covered now.
• Request a formulary exception / appeal if Wegovy isn’t tolerated or effective for you. Documented medical necessity is the key.
• Check a different PBM at open enrollment — Express Scripts and OptumRx already cover Zepbound.
• LillyDirect self-pay vials — the FDA-approved drug at $349–$599/mo depending on dose.
• Compounded tirzepatide — the same molecule from a verified pharmacy. The median is about $199/mo; our editorial pick NexLife holds a flat $186/mo at every dose, with LegitScript certification and labs included. Not FDA-approved — verify credentials first. See our full Zepbound cost breakdown and cost questions hub.

Who should do what

• Covered for GLP-1s and on Wegovy: ask whether to switch back to Zepbound after Oct 1 — if tirzepatide worked better for you, the $25 copay makes it an easy call.
• On Medicare: mark July 1 — the $50 GLP-1 Bridge copay is likely your cheapest legitimate path.
• Plan excludes weight-loss GLP-1s (or you’re uninsured): the formulary news doesn’t help you. A flat compounded plan such as NexLife is usually the lowest cash cost to the same molecule — confirm your maintenance-dose price and the pharmacy’s credentials.

Frequently asked questions

Does CVS Caremark cover Zepbound in 2026?

Not on its standard formularies yet. CVS Caremark removed Zepbound in July 2025 and kept it excluded through most of 2026, preferring Novo Nordisk’s Wegovy. That reverses on October 1, 2026, when Zepbound returns as a co-preferred option. Separately, the oral GLP-1 Foundayo was added on June 1, 2026.

When will CVS Caremark cover Zepbound again?

October 1, 2026. Zepbound returns to CVS Caremark’s standard commercial formulary template, which covers roughly 25–30 million Americans, as a co-preferred GLP-1 alongside Wegovy. Being on the template doesn’t guarantee your specific plan covers it — employers can still opt out.

How much will Zepbound cost with CVS Caremark?

For eligible commercially insured members, Zepbound (and Foundayo) are expected to cost about $25 a month once covered. Medicare Part D beneficiaries can pay a flat $50 a month for Wegovy or Zepbound through the new GLP-1 Bridge program, which runs from July 1, 2026 through the end of 2027.

What if my employer opts out of GLP-1 coverage?

“Co-preferred” means the drug is on the template, not that your plan pays for it — self-funded employers can still exclude GLP-1s for weight loss. If you’re not covered, your cash options are LillyDirect vials ($349–$599), the Lilly Savings Card, or compounded tirzepatide — the same molecule — from a verified provider such as NexLife at $186 a month flat.

Is there a cheaper option than Zepbound right now?

If you’re paying cash, yes. Compounded tirzepatide is the same active ingredient as Zepbound at a fraction of the price — a median near $199 a month, with verified flat plans like NexLife at $186 a month. It is not FDA-approved and is not the same product as Zepbound, so confirm the pharmacy’s credentials before enrolling.

Does the change affect Mounjaro or other PBMs?

No. Mounjaro (tirzepatide for type 2 diabetes) was never dropped, since the exclusion only applied to the weight-loss brand Zepbound. The other two large pharmacy benefit managers, Express Scripts and OptumRx, already cover Zepbound.

Sources

• CVS Health — “CVS Caremark delivers affordability and access to GLP-1 weight management medications with expanded coverage options,” company news release, May 28, 2026.
• Reporting on the reversal and copay terms: Boston Globe, NBC News, FiercePharma (May 2026).
• 2025 exclusion and lawsuit background; PBM coverage (Express Scripts, OptumRx); Medicare GLP-1 Bridge program details.
• GLP-1 Cost Guide pricing dataset — see our methodology, price database, and Zepbound cost guide.

Educational content, not medical or insurance advice. Coverage, copays, and formulary status vary by plan and change frequently — confirm details directly with CVS Caremark and your plan. Compounded tirzepatide is not FDA-approved and is not the same product as Zepbound. Talk to a licensed clinician before starting, stopping, or changing any medication.